How to Track Whether Your HRT Is Actually Working: Objective Biomarkers Beyond Symptoms

HRT works on two levels: symptom relief and biological restoration. Most women, and many clinicians, only measure the first. Symptoms like hot flashes, sleep disruption, and mood changes are real and important, but they are subjective, variable, and incomplete as evidence that HRT is doing what it needs to do at a molecular level. The deeper question is whether hormone therapy is slowing the immune aging and chronic inflammation that menopause accelerates, and that requires objective measurement.

This article answers the questions women and their clinicians most commonly ask when they want to move beyond symptom tracking and into data-driven HRT management. For a comprehensive overview of how hormonal changes affect biological aging and how to track them, see Menopause, HRT & Biological Age: The Definitive Guide to Tracking Hormonal Aging.

Why can't I just go by how I feel on HRT?

Symptoms are a starting point, not a finish line. Dr. Louise Newson, a leading menopause specialist, has noted that hormone levels during perimenopause fluctuate so dramatically, sometimes daily, that blood tests can be "falsely misleading." Symptoms themselves also vary so widely across women that clinical assessment alone often leaves both patient and clinician without reliable guidance. A woman can feel better on HRT while her immune system continues to age at an accelerated rate; conversely, a formulation change that produces no immediate symptom shift may be driving meaningful biological improvement. Feeling well is the goal, but it is not the same as biological restoration.

"I would love to monitor my patients before they start HRT. We want to know how quickly we can reverse this pro-inflammation — and inflammation is crucial to our future health."

— Dr. Louise Newson, GP and Menopause Specialist, Newson Health

What objective biomarker actually shows whether HRT is working at a biological level?

GlycanAge, which measures biological age based on IgG glycosylation (the pattern of complex sugars attached to immune antibodies), is the most direct available measure of whether HRT is reducing the chronic inflammation that menopause drives. Unlike FSH or estradiol blood tests, which capture a single hormonal snapshot and fluctuate hour to hour, GlycanAge reflects the cumulative biological effect of hormonal and metabolic changes over months. This makes it uniquely suited to HRT monitoring: it tells you not what your hormone levels are right now, but whether your immune system is responding to treatment over time.

How does menopause actually change my biology, and why does that matter for HRT?

Menopause disrupts IgG glycosylation (the molecular switches that regulate inflammation) by decreasing anti-inflammatory glycans while increasing pro-inflammatory ones.

"What we are looking at is biological aging, but what we are actually measuring is the age of the immune system. This is very pronounced in the transition from regular menstrual cycles to menopause — women age biologically when they lose the protective power of sex hormones."

— Dr. Julija Jurić, Molecular Biologist, Genos Glycoscience Research Laboratory

This shift is driven by the complex interplay of estrogen deficiency and, in early perimenopause, relative estrogen dominance, characterized by intermittent estradiol peaks alongside a marked decline in progesterone, which begins to fall before estrogen as ovulation becomes irregular.

Hormonal balance matters as much as absolute hormone levels. The result is accelerated immune aging, measurable years before cardiovascular, metabolic, or autoimmune disease becomes clinically apparent. HRT, when optimized, can reverse these glycan changes, with clinical data showing biological age reductions of 5 to 25 years in women on well-managed estradiol protocols.

How much can HRT actually change my biological age, and how quickly?

The evidence from clinical practice is specific. At Raffaele Medical, a longevity clinic in New York City, GlycanAge testing has been incorporated into HRT management for hundreds of patients. In one documented case, a 55-year-old woman four years post-menopause switched from oral estrogen–progesterone therapy to bioidentical estradiol cream; her GlycanAge decreased by 10 biological years over 12 months. This shift is not visible from symptoms alone. In a second case, a 56-year-old woman who had never used HRT initiated a regimen of transdermal estradiol, testosterone, DHEA, and progesterone; her GlycanAge reduced by 8 years within three months and by 11 years at one year. These outcomes demonstrate that meaningful biological change is measurable within the timeframe of standard clinical follow-up.

When should I get a GlycanAge test relative to starting or changing HRT?

The clinical protocol is to baseline before initiating HRT, then retest at six-month intervals to monitor effectiveness. A baseline measurement before treatment establishes the starting point; without it, any subsequent result is difficult to interpret. Where a GlycanAge result is meaningfully elevated above chronological age, this indicates accelerated immune aging and supports a clinical conversation about intervention, whether lifestyle-based or hormonal.

Rising values after initiating HRT may indicate suboptimal dosing or a formulation that is not adequately restoring hormonal balance. For women already on HRT who have not yet baselined, the first test still provides actionable data. It tells you where you are now and gives you a benchmark for the next retest.

For pharmaceutical interventions including HRT, glycan shifts can be detectable within 3–4 months, making an earlier retest appropriate when initial dose optimization is the clinical priority.

"What I love about the GlycanAge test is that you can see changes within three months, and they're quite stable. The changes occur quickly — you can see them, monitor what you're doing, and alter your therapy if you need to."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical

For more on what to expect from testing during perimenopause and menopause, see our guide to testing for menopause.

Does the type or route of HRT matter for biological age outcomes?

Formulation and route of administration both influence downstream glycan biology. Transdermal estradiol is preferred over oral where possible, partly because oral estrogen carries a higher venous thromboembolism risk.

The clinical cases above illustrate this directly: switching from oral to transdermal bioidentical estradiol produced a 10-year GlycanAge reduction in a patient whose symptoms had not resolved on oral therapy. Progesterone, androgens, and adrenal hormones each modulate immune tone independently of estradiol, which is why a personalized multi-hormone approach, rather than estrogen alone, may be required to achieve full glycan restoration. Clinicians looking to integrate GlycanAge into hormone therapy protocols can find detailed guidance on our hormone tracking for healthcare providers page.

Can GlycanAge help my clinician decide whether to adjust my HRT dose?

Yes, and this is one of its most practical clinical applications. GlycanAge provides objective support for HRT titration decisions: a lack of improvement in glycan results after initiating therapy can indicate the need for dose adjustment, a formulation change, or broader evaluation of lifestyle and metabolic factors. The clinical decision framework used at specialist menopause clinics incorporates GlycanAge as an objective guide for dosing and monitoring response, replacing guesswork with a measurable signal of whether therapy is working.

If you are managing menopause, whether you are newly perimenopausal, already on HRT, or considering a formulation change, a GlycanAge test gives you and your clinician the biological data to make those decisions with confidence.

Order your at-home test kit and book your included 1:1 Result Interpretation Call.

External sources

• https://www.cell.com/iscience/fulltext/S2589-0042(22)00167-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004222001675%3Fshowall%3Dtrue — Deriš H, Kifer D, Cindrić A, Petrović T, Cvetko A, Trbojević-Akmačić I, Kolčić I, Polašek O, Newson L, Spector T, Menni C, Lauc G. Immunoglobulin G glycome composition in transition from premenopause to postmenopause. iScience. 2022;25(3):103897.

• https://www.jvsvenous.org/article/S2213-333X(18)30387-1/fulltext — Rovinski D, Ramos RB, Fighera TM, Casanova GK. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2018.